These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32133275)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.
    Shinagare AB; Barysauskas CM; Braschi-Amirfarzan M; O'Neill AC; Catalano PJ; George S; Ramaiya NH
    Clin Imaging; 2016; 40(5):880-4. PubMed ID: 27179958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
    Kim HD; Kim BJ; Kim HS; Kim JH
    Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
    Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
    Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
    Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer.
    Khokher S; Qureshi MU; Chaudhry NA
    Asian Pac J Cancer Prev; 2012; 13(7):3213-8. PubMed ID: 22994736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
    Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria.
    Puranik AD; Purandare NC; Shah S; Agrawal A; Rangarajan V
    Indian J Nucl Med; 2015; 30(1):21-5. PubMed ID: 25589801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
    AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor response evaluation in oncology: current update.
    Shanbhogue AK; Karnad AB; Prasad SR
    J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
    Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT
    Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
    Kim JH; Kim BJ; Jang HJ; Kim HS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.
    Serkova NJ
    Drug Resist Updat; 2011; 14(4-5):224-35. PubMed ID: 21640633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of liver tumor response to therapy: role of quantitative imaging.
    Gonzalez-Guindalini FD; Botelho MP; Harmath CB; Sandrasegaran K; Miller FH; Salem R; Yaghmai V
    Radiographics; 2013 Oct; 33(6):1781-800. PubMed ID: 24108562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.